Printer Friendly

Nihon Schering, Daiichi Radioisotope Laboratories to Collaborate in Sales of Radioimmunotherapy Agent Zevalin.

Tokyo, Japan, July 10, 2006 - (JCN) - Nihon Schering announced on June 4 that it signed a joint business contract with Daiichi Radioisotope Laboratories (DRL) regarding Zevalin, a radioimmunotherapy agent used in the treatment of non-Hodgkin's lymphoma.

Zevalin (ibritumomab tiuxetan), which was initially approved in the US in 2002, is currently available in 37 countries worldwide.

Nippon Schering has applied a new drug application for Zevalin with the Ministry of Health, Labor and Welfare, as of June 23, and aims to obtain approval at the earliest date possible.

Upon receiving approval, the two companies will jointly promote and sell Zevalin in Japan. In particular, DRL will handle orders and distribution.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Jul 10, 2006
Words:119
Previous Article:So-net M3, Senior Communication Introduce AskDoctors R50 Medical Consultation Service for Seniors.
Next Article:Taiho Pharmaceutical, Sanofi-aventis Conclude Licensing Agreement for Oral Pyrimidine Fluoride-derived Anticancer Agent TS-1.


Related Articles
EUROPEAN COMMISSION APPROVES ZEVALIN RADIOIMMUNOTHERAPY.
Terumo Acquires Exclusive Sales Rights for Three Contrast Agents from Guerbet AG.
UCB Japan, Daiichi Pharmaceutical to Reinforce Their Collaboration for Antiallergic Agent Zyrtec.
Daiichi Pharmaceutical, GE Healthcare to Collaborate in R&D for Contrast Media.
Daiichi Wins Lawsuit Against Mylan Pharmaceuticals Regarding Patents for Levofloxacin.
Fujifilm Acquires Daiichi Radioisotope Laboratories, Diagnostic Radiopharmaceuticals Manufacturer.
Daiichi Sankyo Announces Completion of Phase I Trial on the Anti-influenza Drug CS-8958.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters